Gynazole (Butoconazole nitrate) is commonly used in situations involving certain distressing symptoms associated with Vulvovaginal Candidiasis (VVC), or a yeast infection. Its use is relevant for managing conditions characterized by periods of heightened symptoms associated with VVC, and is applied across conditions involving episodic or fluctuating manifestations, including uncomplicated and certain recurrent or severe symptomatic burden. This antifungal agent is considered relevant in contexts marked by increased localized discomfort.

The medication is commonly used to help address symptom clusters that create noticeable physiological strain and may interfere with daily comfort. This includes specifically groups of symptoms that may become disruptive, such as vaginal and vulvar itching (pruritus), burning, and symptoms related to inflammatory or irritative states like redness and soreness. Gynazole generally provides supportive relief that helps ease the overall symptom burden. It provides supportive relief that helps patients cope more steadily with symptom fluctuations when symptoms become more noticeable during acute episodes.

---

Quick Fact: Relief for Vulvovaginal Discomfort

Symptom Domain	General Benefit
Symptoms of Localized Irritation	Assists with managing physical signs of irritation.
Itching and burning	Provides supportive relief to ease daily functional strain.
Abnormal discharge	Helps manage discharge associated with the irritative process.

Eligibility Map: Who can and cannot use Gynazole — official regulatory information

Section	Official Regulatory Statement
Populations for whom use is allowed:	Non-pregnant women are the population in whom the product is explicitly stated to be safe and effective.
Populations for whom use is contraindicated:	Patients with a history of hypersensitivity to butoconazole nitrate or to any of the product's components.
Age-related eligibility rules:	Safety and effectiveness in children have not been established. Use in non-pregnant adults is established.
Pregnancy and lactation eligibility status:	Pregnancy: Category C status; use is restricted to only if the potential benefit justifies the potential risk to the fetus. Lactation: Caution should be exercised, as excretion in human milk is not known.
Eligibility-related restrictions:	Use by patients with recurrent vaginal yeast infections requires further medical evaluation to rule out underlying conditions, such as HIV, before proceeding with treatment.

---

Connection to the overall eligibility profile

The official regulatory profile classifies this medicine as established for use in non-pregnant adult women. Absolute non-eligibility is defined solely by a history of hypersensitivity to the components of the cream. Use in the pediatric population is subject to restriction as safety and effectiveness have not been established. Furthermore, use during pregnancy (Category C) and lactation requires caution and a clinical assessment because safety data is limited and excretion in human milk is not known. Patients with recurrent infections must undergo further evaluation to confirm diagnosis and rule out underlying systemic conditions.

Gynazole (Butoconazole nitrate) is a topical vaginal cream. Due to the product's localized route of administration and minimal systemic absorption, the official regulatory profile documents no systemic drug-drug interactions with orally or injectable administered medicines. Consequently, there are no formal restrictions or cautions listed in the prescribing information concerning interactions mediated by human metabolic pathways, such as CYP enzymes, or those involving drug transporters. The sole documented interaction is non-systemic, focusing on a product-level chemical incompatibility between the cream and certain medical devices, which is essential to understand for correct use.

---

Interaction Context	Official Regulatory Information
Systemic Drug Interactions	None documented. No systemic drug-drug, metabolic, or transporter-mediated interactions are listed.
Physical/Chemical Interaction	The cream contains mineral oil, an excipient documented to compromise the material integrity of products made of latex or rubber.
Affected Products	Barrier contraceptive devices, specifically condoms and vaginal contraceptive diaphragms, are affected by this interaction.
Timing Restriction	Use of these latex or rubber barrier products is not recommended within 72 hours following the administration of the cream.

---

The mandatory timing separation is the only official restriction detailed in the prescribing information. This measure is necessary to prevent the mineral oil from weakening the structural composition and reducing the efficacy of the barrier method. Regulatory documentation contains no specific warnings regarding interactions with food, alcohol, herbal supplements, or specific patient populations.

The action of butoconazole nitrate is defined by its interference with the fundamental biology of the fungal organism, resulting in cellular destruction.

Blocking the Ergosterol Biosynthesis Pathway

The core mechanism involves butoconazole acting as a non-competitive inhibitor of lanosterol 14-alpha demethylase (CYP51), a crucial enzyme within the fungal cell's endoplasmic reticulum. This blockade halts the conversion of lanosterol into ergosterol, a primary sterol essential for fungal cell membrane integrity. The inhibition causes a cascade of molecular injury within the organism.

Compromising Fungal Cell Membrane Integrity

The resulting ergosterol depletion and accumulation of toxic sterol precursors alters the membrane's lipid composition, leading to a critical loss of its barrier function. This compromise results in osmotic disruption and leakage of cellular contents, producing a concentration-dependent sequence of fungistasis (growth cessation) followed by cell lysis. This structural damage is the final mechanistic consequence of the drug’s action at the cellular level.

How Gynazole is Used

Butoconazole nitrate vaginal cream (Gynazole) is designated for intravaginal administration only, utilizing the product’s specific 2% cream formulation. The medicine is provided in a prefilled disposable applicator and is designed for a short-term, single-application treatment course to complete the regimen.

---

Standard Administration Pattern

For non-pregnant adults, the standard regimen involves applying one applicatorful of the cream, which is approximately 5 grams of the 2% formulation. This single application delivers approximately 100 milligrams of butoconazole nitrate. The application is generally instructed to be performed at bedtime for optimal patient convenience.

---

Procedural and Population Constraints

Constraint Area	Official Instruction Summary
Application Timing	Typically administered as a single dose at bedtime.
Vehicle Interaction	The cream contains mineral oil, which may weaken latex or rubber products (condoms, diaphragms); avoidance is necessary for 72 hours after treatment.
Pediatric Use	Safety and effectiveness have not been established in patients under 18 years of age.

For certain pregnant women in their second or third trimester, a modified treatment pattern of once daily for six days may be prescribed, differing from the single-dose regimen intended for non-pregnant women. The official instruction for the standard dose establishes a precise application method: the cream is inserted high into the vagina, often directed toward the posterior vaginal fornix, ensuring localized delivery of the active ingredient. The single-dose administration defines the entirety of the treatment course.

Research Evidence / Overview of Studies for Gynazole

Evidence for Use in Vulvovaginal Candidiasis (VVC)

Research exploring Butoconazole nitrate (Gynazole) has primarily relied on Randomized Controlled Trials (RCTs). These are formal studies designed to examine outcomes in adult, non-pregnant women with symptomatic yeast infections caused mainly by the Candida fungus. Studies were conducted during periods of increased symptom activity, and researchers monitored responses over defined time intervals.

The central aim of these studies was to assess outcomes related to physical discomfort and to conditions where symptoms may vary in intensity. Researchers focused on measuring Therapeutic Cure, which combines two distinct endpoints: the resolution of visible signs and symptoms (called Clinical Cure) and the laboratory confirmation that the fungus has been eliminated from the affected area (called Mycological Eradication). Research reports how symptoms evolved in the observed populations. Findings describe patterns observed in the studies related to symptom intensity and variability.

Study Comparisons with Other Antifungal Treatments

Comparative clinical trials were conducted to evaluate Butoconazole nitrate in research scenarios involving other established local treatments, such as other topical azole antifungals and, in some studies, single-dose oral treatments. Research highlights that measured rates of Clinical Cure in these comparative studies were observed in patterns related to other topical antifungal creams and tablets. However, research describes that findings were sometimes mixed when studies monitored Mycological Eradication rates.

What is Still Uncertain About the Research

Long-term effects are not fully established, as follow-up durations were limited in the main studies. Limited information exists for the outcomes in women with complicated forms of yeast infection, such as those with highly recurrent episodes. Additionally, while the research examined VVC caused mainly by Candida albicans, there is less extensive data reported on the measured outcomes for less common Candida species.

Common questions about Gynazole (FAQ)

Q: How quickly does Gynazole start to work?

A: Clinical studies have examined the onset of relief after using Gynazole. Research findings indicate that 75% of women experienced the first relief of their symptoms within approximately 24 hours of administration. These findings describe patterns related to the onset of relief.

Q: How long do the effects of Gynazole typically last?

A: The formulation of the cream is designed to release the medication slowly into the affected area over approximately four days. Following administration, peak levels of the drug in the bloodstream (plasma) are typically reached between 12 and 24 hours. The single-dose administration is designed to deliver the treatment based on this duration.

Q: What are common side effects people report after using Gynazole?

A: According to official regulatory documentation, common side effects are generally localized to the application area. In clinical studies, 5.7% of patients reported complaints, including vulvar or vaginal burning, itching, soreness, swelling, or pelvic and abdominal pain or cramping.

Q: Can Gynazole cause a burning or itching sensation?

A: Yes, a burning or itching sensation in the vulvar or vaginal area is listed among the localized complaints reported in clinical studies. This type of reaction was observed in a percentage of patients (5.7%) who received the treatment.

Q: Are there warnings about using Gynazole while breastfeeding?

A: Official product information states it is unknown whether this medicine is excreted into human milk. For this reason, the official label describes that caution is advised for use in a nursing woman.

Q: Can Gynazole be used during a menstrual period?

A: It is generally possible to use this medication during a menstrual period. However, official guidance advises against the use of barrier items like tampons or douches during treatment. Official guidance suggests the use of sanitary pads, as the medication is localized.

Q: Does Gynazole contain any hormones?

A: Gynazole does not contain any hormones. The active ingredient, butoconazole nitrate, is classified solely as an azole antifungal agent. The official regulatory label lists the components of the formulation, none of which are hormones.

Q: Do other medications need to be avoided while using Gynazole?

A: Regulatory documents list the chemical incompatibility with latex or rubber products as the primary non-systemic interaction. Additionally, drug interaction data indicates that the use of Gynazole with progesterone vaginal (a hormone replacement product) should be avoided, as it may decrease progesterone levels and efficacy.

Q: Can Gynazole be used for infections in other areas of the body?

A: Gynazole is specifically indicated and approved only for the localized treatment of vulvovaginal candidiasis (VVC), which is a yeast infection. Regulatory documents state the product is a vaginal cream and is only used in the vagina.

Q: Are there any known side effects that affect sex drive or mood?

A: Official regulatory documentation for adverse reactions lists localized and gastrointestinal complaints, such as burning, itching, and pelvic pain. Changes in sex drive or mood are not listed among the side effects reported in the official product information.

Q: Is it possible for the infection to come back after using Gynazole?

A: Recurrent vaginal fungal infections are a recognized possibility. The official label discusses recurrence as a possibility and notes that if symptoms persist or return, testing is indicated to confirm the diagnosis and to rule out other possible underlying conditions.

Q: Is there any research on long-term effects of Gynazole use?

A: The long-term effects of Gynazole have not been fully established in research. Official regulatory documentation indicates that long-term studies to evaluate the drug's carcinogenic potential have not been performed in animals. Furthermore, the main human clinical studies had limited follow-up durations.

Q: Are there different strengths of Gynazole available?

A: Gynazole is officially supplied as butoconazole nitrate vaginal cream, 2%. This specific 2% strength is the formulation administered in the standard single-dose treatment regimen. No other strengths are specified in the official dosing information.

Q: Do I need to change my diet while using Gynazole?

A: Official regulatory documentation contains no specific warnings or restrictions regarding interactions with food or drink while using this product. No changes to the diet are explicitly mentioned as a requirement for use.

Q: What should be done if I miss a scheduled part of the treatment?

A: For the standard treatment regimen, Gynazole is administered as a single dose. This means there is no multi-day or daily dosing schedule that a patient would need to track or worry about missing.

Q: What age group is Gynazole generally approved for?

A: The use of Gynazole is established for non-pregnant adult women. The official documents state that safety and effectiveness for patients under the age of 18 years have not been established.

How to Store and Dispose of Gynazole?

Gynazole-1 (butoconazole nitrate) vaginal cream, 2%, must be stored under specific conditions to maintain its integrity.

Storage Requirement	Specification
Temperature	Store at 25 C (77 F); excursions permitted between 15 C and 30 C (59 F–86 F).
Environmental Constraints	Do not freeze and avoid heat above 30 C. Store away from excess moisture.
Packaging	Keep the product in the original container and ensure it is tightly closed. Do not use if the protective foil over the applicator is broken.
Child Safety	Keep this medication out of the sight and reach of children.

Expired or unused medication must be thrown away according to official regulatory guidelines, preferably using a medicine take-back program. The cream should not be flushed down the toilet.